fda glp-1 compounding restrictions
Prescription Weight Loss Reviewed: Is FDA Sudden?
Yes, the FDA’s latest moves feel sudden: it is pulling semaglutide, tirzepatide and liraglutide out of the 503B bulk-drug list, a step that could shutter many compounding operations overnight. The shift follows a series of proposals announced in early 2026 to tighten control over GLP-1 weight-loss agents. Medical Disclaimer: